Targeting genomic instability in cancer

A comprehensive review published in Cell examines the evolving landscape of therapies targeting genomic instability, a fundamental hallmark of cancer. The article traces the therapeutic arc from traditional chemotherapy and radiation through PARP inhibitors for DNA-repair-deficient tumors to newer modalities such as antibody-drug conjugates and radiopharmaceuticals. The authors highlight how precision medicine approaches now emphasize rigorous patient selection and rational drug combinations to widen the therapeutic index. While no novel clinical data are presented, the review synthesizes current knowledge and outlines strategies for improving outcomes across multiple tumor types. The work provides a valuable framework for clinicians and researchers navigating the rapidly expanding toolkit against genomically unstable cancers.